GALT icon

Galectin Therapeutics
GALT

Overview Fund Trends Analyst Outlook Journalist POV

80 hedge funds and large institutions have $34.4M invested in Galectin Therapeutics in 2019 Q3 according to their latest regulatory filings, with 13 funds opening new positions, 29 increasing their positions, 19 reducing their positions, and 9 closing their positions.

New
Increased
Maintained
Reduced
Closed

more repeat investments, than reductions

Existing positions increased: | Existing positions reduced:

more first-time investments, than exits

New positions opened: | Existing positions closed:

more funds holding

Funds holding: →

more ownership

Funds ownership: →

3% less capital invested

Capital invested by funds: $35.4M → $34.4M (-$932K)

43% less call options, than puts

Call options by funds: $665K | Put options by funds: $1.17M

Holders
80
Holders Change
Holders Change %
% of All Funds
Holding in Top 10
–
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
Increased
Reduced
Closed
Calls
$665K
Puts
$1.17M
Net Calls
Net Calls Change

Top Buyers

1
+$1.3M
2
+$924K
3
+$294K
4
Bank of Montreal
Bank of Montreal
Ontario, Canada
+$289K
5
State of Wisconsin Investment Board
State of Wisconsin Investment Board
Wisconsin
+$189K

Top Sellers

1
-$614K
2
-$144K
3
-$121K
4
AG
Advisor Group
Arizona
-$111K
5
CS
Credit Suisse
Switzerland
-$72K
Name Holding Trade Value Shares
Change 		Change in
Stake
76
$147
77
–
78
–
79
–
80
–
81
–
82
–
83
–
84
–
85
–
1 2 3
4